Edurant is an Antiretroviral Agent, Reverse Transcriptase Inhibitor (Non-nucleoside) used in the treatment of HIV-1 infections. Rilpivirine has activity against HIV-1 by binding to reverse transcriptase. It consequently blocks the RNA-dependent and DNA-dependent DNA polymerase activities, including HIV-1 replication. It does not require intracellular phosphorylation for antiviral activity.

Pre-Authorization Criteria:

Treatment of HIV-1 infections in antiretroviral treatment-naïve patients with HIV-1 RNA less than or equal to 100,000 copies/mL at the start of therapy

Note: to be used in combination with at least 2 other antiretroviral agents. Note: VCHCP requires that Edurant be prescribed by an Immunology Clinic physician with current American Academy of HIV Medicine (AAHIVM) certification or a physician boarded in Infectious Disease.

Note: not recommended for patients less than 18 years of age

Dosing: Adult:
Treatment of HIV-1 infection: Oral: 25 mg once daily.

Dosing: Pediatric:
Pediatric dosing is currently unavailable or not applicable

Dosing: Renal Impairment:
Mild-to-moderate renal impairment: No dosage adjustment necessary.
Severe or end-stage renal impairment: Use with caution; no dosage adjustment necessary (DHHS, 2012)
Hemodialysis/peritoneal dialysis: Due to extensive protein binding, significant removal by hemodialysis or peritoneal dialysis is unlikely.

Dosing: Hepatic Impairment:
Mild-to-moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.
Severe impairment (Child-Pugh class C): No dosage adjustment provided in the manufacturer’s labeling (has not been studied); DHHS HIV guidelines also have no dosage recommendation (DHHS, 2012).
**Dosage Forms: U.S.:**
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Tablet, Oral:
Edurant: 25 mg

Generic Equivalent Available: U.S.-No

**Administration:**
Administer with a normal- to high-calorie meal. Taking with a protein supplement drink alone does not increase absorption.

**Contraindications:**
Current use of carbamazepine, dexamethasone (>1 dose), oxcarbazepine, phenobarbital, phenytoin, proton pump inhibitors (PPIs), rifabutin, rifampin, rifapentine, or St. John’s wort.

**Adverse Reactions:**
>10%-cholesterol increased, LDL increased, ALT increased, AST increased
Other Serious Less Common Reactions: Depression, suicidality, fat redistribution, hepatotoxicity, immune reconstitution syndrome, autoimmune disorders.

**Exclusions:**
Edurant is not for use in treatment-experienced patients.

**References:**


11. [www.epocrates.com](http://www.epocrates.com): Edurant Drug Information

**REVISION HISTORY:**

Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD
Date Approved by P&T Committee: 1/27/15
Date Reviewed/Updated: 3/3/15 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/26/16
Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/24/17
Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/23/18
Date Reviewed/No Updates: 1/22/19 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/22/19
Date Reviewed/No Updates: 2/18/20 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 2/18/20

<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Content Revised (Yes/No)</th>
<th>Contributors</th>
<th>Review/Revision Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/24/17</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>1/23/18</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>1/22/19</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>2/18/20</td>
<td>No</td>
<td>Howard Taekman, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
</tbody>
</table>